

Amendments to the Specification

Please replace the sequence listing with the attached substitute sequence listing.

Please replace the paragraph beginning at page 63, line 22, with the following amended paragraph:

Point Mutations of PYY(3-36)

PEPTIDE	SEQUENCE
PYY(3-36)	IKPEAPGEDASPEELNRYYYASLRHYLNLVTRQRY (SEQ ID NO: 1 <u>SEQ ID NO: 334</u>)
[Leu ³]PYY(3-36)	LKPEAPGEDASPEELNRYYYASLRHYLNLVTRQRY (SEQ ID NO: 189)
[Val ³] PYY(3-36)	VKPEAPGEDASPEELNRYYYASLRHYLNLVTRQRY (SEQ ID NO: 190)

Please replace the paragraph beginning at page 64, line 20, with the following amended paragraph:

Certain preferred NPY analogs have the formula: X-R₁₈-Arg-Tyr-Tyr-R₂₂-R₂₃-Leu-Arg-His-Tyr-R₂₈-Asn-Leu-R₃₁-Thr-Arg-Gln-Arg-Tyr-NH₂ (SEQ ID NO: 342), wherein X is H or C^a Me or N^a Me or desamino or an acyl group having 7 carbon atoms or less; R₁₈ is Ala or Ser; R₂₂ is Ser or Ala; R₂₃ is Ala or Ser; R₂₇ is Phe or Tyr; R₂₈ is Ile or Leu; R₃₁ is Ile or Val; and R₃₆ is Phe or Tyr; provided that at least one of R₂₇ and R₃₆ is Phe. See U.S. Patent No. 5,026,685.

Please replace the paragraph beginning at page 64, line 27, with the following amended paragraph:

Other contemplated NPY analogs have the formula:

X-R₁₇-R₁₈-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-R₂₇-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-R₃₆-NH₂ (SEQ ID NO: 343),

wherein R₁₇ is Arg or Leu and R₁₈ is Ser or Ala or Ile; and wherein X, R₂₇ and R₃₆ are as previously indicated.

Please replace the paragraph beginning at page 65, line 2, with the following amended paragraph:

Still other preferred NPY analogs have the formula:

X-R₁₈-Arg-Tyr-Tyr-Ala-Ser-Leu-R₂₅-His-R₂₇-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-R₃₆-NH₂
(SEQ ID NO: 344),

wherein X is desamino or C^a Me or N^a Me and wherein R₁₈, R₂₅, R₂₇ and R₃₆ are as previously indicated.

Please replace the table beginning at page 75, line 31, with the following amended table:

~~Exemplary~~ Exemplary PYY agonists include:

YPAKEAPGEDASPEELSTYYASLR [im-DNP-His ²⁶] YLNLVTRZRY-NH ₂ PYY(22-36)	(SEQ ID NO: 256)
ASLRHYLNLVTRQRY-NH ₂ [Ala ³²]PYY	(SEQ ID NO: 257)
ASLRHYLNLV[Ala]RQRY-NH ₂ [Ala ^{23,32}]PYY	(SEQ ID NO: 258)
A[Ala]LRHYLNLV[Ala]RQRY-NH ₂ [Glu ²⁸]PYY(22-36)	(SEQ ID NO: 259)
ASLRHY[Glu]NLVTRQRY-NH ₂ N-α-Ac-PYY(22-36)	(SEQ ID NO: 260)
N-α-Ac-ASLRHYLNLVTRORY-NH ₂ N-α-Ac[p.CL.Phe ²⁶]PYY	(SEQ ID NO: 261)
N-α-Ac-ASLR[p.CL.Phe ²⁶]YLNLVTRQRY-NH ₂ N-α-Ac[Glu ²⁸]PYY	(SEQ ID NO: 262)
N-α-Ac-ASLRHY[Glu]NLVTRQRY-NH ₂ N-α-Ac[Phe ²⁷]PYY	(SEQ ID NO: 263)
N-α-Ac-ASLRH[Phe]ENLVTRQR[N-Me-Tyr]-NH ₂	(SEQ ID NO: 264)

N- α -Ac]8N-Me-Tyr ³⁶]PYY	
N- α -Ac-ASLRHYENLVTR0R[N-Me-Tyr]-NH ₂	(SEQ ID NO: 265)
N- α -myristoyl-PYY(2214 36)	
N- α -myristoyl-ASLRHYLNLVTRQRY-NH ₂	(SEQ ID NO: 266)
N- α -naphthateneacetyl-PYY(22-36)	
N- α - naphthateneacetyl-ASLRHYLNLVTRQRY-NH ₂	(SEQ ID NO: 267)
N- α -Ac[Phe ²⁷]PYY	
N- α -Ac-ASLRH[Phe]ENLVTR0R[N-Me-Tyr]-NH ₂	(SEQ ID NO: 268)
N- α -Ac-PYY (22-36)	
N- α -Ac-ASLRHYLNLVTRQRY-NH ₂	(SEQ ID NO: 269)
N- α -Ac-[Bth ²⁷]PYY (22-36)	
N- α -Ac-ASLRH[Bth]LNLVTRQRY-NH ₂	(SEQ ID NO: 270)
N- α -Ac-[Bip ²⁷]PYY (22-36)	(SEQ ID NO: 271)
N- α -Ac-ASLRH[Bth]LNLVTRQRY-NH ₂	(SEQ ID NO: 272)
N- α -Ac-[Nal ²⁷]PYY (22-36)	
N- α -Ac-ASLRH[Bth-Nal]LNLVTRQRY-NH ₂	(SEQ ID NO: 273)
N- α -Ac-[Trp ²⁷]PYY (22-36)	(SEQ ID NO: 274)
N- α -Ac-ASLRH[Trp]LNLVTRQRY-NH ₂	(SEQ ID NO: 275)
N- α -Ac-[Thi ²⁷]PYY (22-36)	
N- α -Ac-ASLRN[Thi]LNLVTRQRY-NH ₂	(SEQ ID NO: 276)
N- α -Ac-[Tic ²⁷]PYY (22-36)	
N- α -Ac-ASLRH[Tic]LNLVTRQRY-NH ₂	(SEQ ID NO: 277)
N- α -Ac-[Phe ²⁷]PYY (25-36)	
N- α -Ac-H[Phe]LNLVTRQRY-NH ₂	(SEQ ID NO: 279)
N- α -Ac-[Phe ²⁷ ,Thi ²⁷]PYY (22-36)	
N- α -Ac-ASLRH[Phe]LNLVTRQR[Thi]-NH ₂	(SEQ ID NO: 280)
N- α -Ac-[Thz ²⁶ ,Phe ²⁷]PYY (22-36)	
N- α -Ac-ASLRH[Thz][Phe]LNLVTRQRY-NH ₂	(SEQ ID NO: 281)
N- α -Ac-[Phe ²⁷]PYY (22-36)	
N- α -Ac-ASLRH[Thz][Phe]LNLVTRQRY-NH ₂	(SEQ ID NO: 282)
N- α -Ac-[Phe ²⁷]PYY (22-36)	
N- α -Ac-[Phe]SLRN[Phe]LNLVTRQRY-NH ₂	(SEQ ID NO: 289)
N- α -Ac-[Tyr ²² ,Phe ²⁷]PYY (22-36)	
N- α -Ac-[Tyr]SLRH[Phe]LNLVTRQRY-NH ₂	(SEQ ID NO: 290)
N- α -Ac-[Trp ²⁸]PYY (22-36)	
N- α -Ac-ASLRHY[Trp]NLVTRQRY-NH ₂	(SEQ ID NO: 291)
N- α -Ac-[Trp ²⁸]PYY (22-36)	
N- α -Ac-ASLRHYLN[Trp]VTRQRY-NH ₂	(SEQ ID NO: 292)
N- α -Ac-[Ala ²⁶ ,Phe ²⁷]PYY (22-36)	

Applicant: Cowley *et al.*
Serial No: 10/501,411
Filed: July 12, 2004
Page 5 of 12

Attorney Docket No: W2023-7044US/ PC070431A

N- α -Ac-ASLR[Ala][Phe]LNLVTRQRY-NH ₂	(SEQ ID NO: 293)
N- α -Ac-[Bth ²⁷]PYY (22-36)	
N- α -Ac-ASLR[Bth]LNLVTRQRY-NH ₂	(SEQ ID NO: 294)
N- α -Ac-[Phe ²⁷]PYY (22-36)	
N- α -Ac-ASLRH[Phe]LNLVTRQRY-NH ₂	(SEQ ID NO: 295)
N- α -Ac-[Phe ^{27,36}]PYY (22-36)	
N- α -Ac-ASLRH[Phe]LNLVTRQR[Phe]-NH ₂	(SEQ ID NO: 296)
N- α -Ac-[Phe ²⁷ , D-Trp ³²]PYY (22-36)	
N- α -Ac-ASLRH[Phe]LNLV[D-Trp]RQRY-NH ₂	(SEQ ID NO: 297)
